2007 NACFC

Thousands of CF physicians, researchers and allied health professionals from around the world gathered in Anaheim, Calif. for the 21st annual North American Cystic Fibrosis Conference. Since 1986, the conference has provided an important opportunity for professionals of all disciplines throughout the CF community to come together to learn from each other and build collaborations. Following are videos of the three plenary sessions.

Plenary Session I - Thurs., Oct. 4

Robert J. Beall, Ph.D., president and CEO of the CF Foundation opens the session with an introduction of the CF drug development pipeline and the potential impact it has on the CF patient population.

Preston W. Campbell, III, M.D., executive vice president for medical affairs at the Foundation presents the Richard C. Talamo Distinguished Clinical Achievement award to both Antoinette Moran, M.D. and Gerald T. O'Connor, Ph.D., D.Sc. for their contributions in the areas of CF care.

Following, Margarida D. Amaral, Ph.D., a world-renowned CF researcher from Lisbon, Portugal, described the state-of-the-art technologies used in her lab to study Delta-F508 CFTR, the most common mutation of the defective protein responsible for CF in her address, "From Basic Science to the Clinic."

Amaral showed correctors produced by Vertex Pharmaceuticals in collaboration with the CF Foundation, improve the production of mature CFTR channel proteins in in vitro cellular systems. Therapies discussed included those in the earliest stages of exploration in the lab to those already in clinical trials.

View this session. (Time: 1:45 minutes)


Plenary Session II - Fri., Oct. 5

Felix Ratjen, M.D., Ph.D. from Toronto, Ontario described a number of CF therapeutics addressing CF lung disease in "CF Drug Development: What's New?” Protection or improvement of lung function was seen in several trials, including denufosol from Inspire Pharmaceuticals and astreonam lysine for inhalation from Gilead Sciences.

Ratjen, however, noted that new trials hinge on the recruitment of many more patient volunteers and that new drugs will only make it to the marketplace with the help of these trial volunteers.

View this session. (Time: 1:20 minutes)


Plenary Session III - Sat., Oct. 6

In the third plenary, “Improving Patient Outcomes Using the Tools We Have Now,” Michael P. Boyle, M.D. of Baltimore, Md., described some results from the CF Foundation's Quality Improvement Initiative.

Boyle reported on the remarkable improvements that two CF care centers made by adopting the treatment policies and philosophies of those care centers with the best nutritional or pulmonary ratings.

View this session. (Time: 58:07 minutes)


System Requirements

To watch these videos, you will need the latest version of Windows Media Player.

back to top